9-hexadecenoic acid | 2091-29-4

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪酸
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 9-hexadecenoic acid
• 英文别名: palmitoleic acid；Palmitoleinsaeure；hexadec-9-enoic acid；9-trans-Hexadecenoic acid;trans-Palmitoleic acid
• CAS: 2091-29-4
• 化学式: C₁₆H₃₀O₂
• 分子量: 254.413
• InChiKey: SECPZKHBENQXJG-UHFFFAOYSA-N

物化性质

• 熔点：
  0.5°C
• 沸点：
  374.4°C (estimate)
• 密度：
  0.8855 (rough estimate)
• 物理描述：
  OtherSolid, Liquid

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  18
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  反油酸甲酯	octadec-9-enoic acid methyl ester	2462-84-2	C19H36O2	296.494
  ——	methyl 9-pentadecenoate	25915-47-3	C16H30O2	254.413
  ——	1,19-nonadec-9-enedioic acid dimethyl ester	57568-16-8	C21H38O4	354.53
  二甲基十八碳-9-烯二酸酯	dimethyl 9-octadecen-1,18-dioate	13481-97-5	C20H36O4	340.503
  ——	9-eicosenoic acid methyl ester	10340-21-3	C21H40O2	324.547
  月桂酸甲酯	methyl 11-dodecenoate	29972-79-0	C13H24O2	212.332
  壬二酸	azelaic acid	123-99-9	C9H16O4	188.224
  棕榈酸	1-hexadecylcarboxylic acid	57-10-3	C16H32O2	256.429
  十六碳二酸	thapsic acid	505-54-4	C16H30O4	286.412
  庚酸	oenanthic acid	111-14-8	C7H14O2	130.187

反应信息

• 作为反应物：
  描述：

  9-hexadecenoic acid 在 potassium permanganate 作用下， 生成 9,10-二羟基十六烷酸
  参考文献：
  名称：

  Bull, Chemische Berichte, 1906, vol. 39, p. 3573

  摘要：

  DOI：

文献信息

• [EN] TARGETED DELIVERY AND PRODRUG DESIGNS FOR PLATINUM-ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF<br/>[FR] ADMINISTRATION CIBLÉE ET CONCEPTIONS DE PROMÉDICAMENTS POUR COMPOSÉS ANTICANCÉREUX À BASE DE PLATINE ET D'ACRIDINE ET MÉTHODES ASSOCIÉES
  申请人：WAKE FOREST SCHOOL OF MEDICINE

  公开号：WO2013033430A1

  公开（公告）日：2013-03-07

  Acridine containing cispiaiin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective eisp!aiin compounds to the nucleus in cancer ceils is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C i^aikylene-phenyl-NH-C(0)-R.15, folic acid, av03 iniegriii RGD binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazol.es, oxazoies, erlotinib, and/or mixtures thereof; wherein R]§ is a peptide.

  含有环丙啶结构的吖啶类化合物已被披露，显示出比其他顺铂类化合物更有效地对抗癌症。使用一种或多种氨基酸、一种或多种糖、一种或多种聚合醚、C i^aikylene-phenyl-NH-C(0)-R.15、叶酸、av03整合RGD结合肽、他莫昔芬、恩多西芬、表皮生长因子受体、抗体结合物、激酶抑制剂、二唑类化合物、三唑类化合物、噁唑类化合物、厄洛替尼和/或它们的混合物将这些更有效的吖啶类化合物传递到癌细胞核中的方法被披露；其中R]§是一个肽。
• Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
  申请人：——

  公开号：US20030069170A1

  公开（公告）日：2003-04-10

  Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

  描述了包括药物-寡聚物共轭物、脂肪酸成分和胆盐成分的药物组合物。药物以共价键连接到寡聚物基团上。脂肪酸成分和胆盐成分以1:5至5:1的重量比存在。还提供了利用这种药物组合物治疗需要此类治疗的受试者的方法，以及提供这种药物组合物的方法。
• Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
  申请人：——

  公开号：US20030229009A1

  公开（公告）日：2003-12-11

  Methods for synthesizing proinsulin polypeptides are described that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also provided as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates and other pro-polypeptide-oligomer conjugates are also provided.

  描述了合成前胰岛素多肽的方法，包括将包括胰岛素多肽和一个或多个肽段的前胰岛素多肽与一个寡聚体接触，这些肽段通过肽键结合，可以被切割以产生胰岛素多肽，条件足以将寡聚体与前胰岛素多肽的胰岛素多肽部分结合并提供前胰岛素多肽-寡聚体共轭物，并从前胰岛素多肽-寡聚体共轭物中切割一个或多个肽段，以提供胰岛素多肽-寡聚体共轭物。还提供了合成前胰岛素多肽-寡聚体共轭物的方法，以及前胰岛素多肽-寡聚体共轭物。还提供了合成C肽多肽-寡聚体共轭物和其他前多肽-寡聚体共轭物的方法。
• [EN] PROCESS FOR PREPARING CARBOXYLIC ACID ESTERS IN THE PRESENCE OF A TITANIUM-CONTAINING CATALYST<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ESTERS D'ACIDES CARBOXYLIQUES EN PRÉSENCE D'UN CATALYSEUR CONTENANT DU TITANE
  申请人：SIBUR HOLDING PUBLIC JOINT STOCK CO

  公开号：WO2016043616A1

  公开（公告）日：2016-03-24

  The present invention relates to a process for preparing carboxylic acid esters, comprising esterification of a carboxylic acid with an alcohol in the presence of a titanium-containing catalyst selected from compounds of a general formula, Tin(OR)x(OR')xOy, wherein n is an integer from 1 to 4; у is an integer from 0 to 6; x can be the same or different and is an integer from 2 to 8; R is a linear or branched C1-C18alkyl, C3-C18cycloalkyl, R' is aryl optionally comprising an electron-donor substituent; or a mixture thereof, with the proviso that if n is 1, then x is 2 and у is 0; and if n>1, then the compounds comprise at least two alkoxy groups and two aryloxy groups. The present invention also relates to a process for preparing carboxylic acid esters, wherein a compound of general formula (I) or (II), wherein q represents an integer of 1 to 4; Y is independently R or R'; or a mixture thereof, with the proviso that the compounds comprise at least two alkoxy groups and two aryloxy groups, is used as a catalyst. The claimed process allows to reduce the amount of a used catalyst and the time of the process duration, while increasing the conversion rate of initial reagents and the yield of a target product.

  本发明涉及一种制备羧酸酯的方法，包括在存在选择自通式Tin(OR)x(OR')xOy的化合物的钛催化剂的情况下，将羧酸与醇酯化，其中n为1至4的整数；у为0至6的整数；x可以相同也可以不同，为2至8的整数；R为线性或支链的C1-C18烷基，C3-C18环烷基，R'为芳基，可包含电子给体取代基；或二者的混合物，但若n为1，则x为2且у为0；若n>1，则化合物至少包含两个烷氧基和两个芳氧基。本发明还涉及一种制备羧酸酯的方法，其中通式(I)或(II)的化合物，其中q表示1至4的整数；Y独立地为R或R'；或二者的混合物，但化合物至少包含两个烷氧基和两个芳氧基，被用作催化剂。所述方法允许减少使用的催化剂量和过程持续时间，同时提高初始试剂的转化率和目标产品的产率。
• COMPOUNDS AND USES THEREOF
  申请人：Yumanity Therapeutics, Inc.

  公开号：US20190330198A1

  公开（公告）日：2019-10-31

  The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本发明涉及用于治疗神经系统疾病的化合物。本发明的化合物可以单独或与其他药用活性剂结合使用，用于治疗或预防神经系统疾病。